Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QuANTUM-R: Quizartinib vs Salvage Chemotherapy in Relapsed/Refractory FLT3-ITD+ AML
NCT02039726Phase 3Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- May 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 19
01
Overview
A Phase 3 trial of quizartinib in acute myeloid leukemia (AML), sponsored by Daiichi Sankyo Co., Ltd.. Started May 2014; status: completed.
02
Drugs
quizartinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02039726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02039726.